NU652 Unit 9 Levetiracetam vs Fosphenytoin Example

When the Trial Calls a Draw: An Evidence Comparison of Levetiracetam and Fosphenytoin for Established Status Epilepticus in a 69-Year-Old Taking Apixaban

[Student Name]

Purdue University Global

NU652: AGACNP Acute Care Diagnosis and Management II

Unit 9 Evidence Comparison Paper

[Instructor Name]

[Date]

The patient is composite; doses, times and values are bracketed.

Introduction and Question

Established status epilepticus is seizure activity that continues after an adequate dose of a benzodiazepine. Mr. [V.] is a [69]-year-old man with atrial fibrillation on apixaban [5 mg] twice daily, hypertension and a remote stroke, who had a generalized convulsive seizure at home and a second in the ambulance without regaining consciousness. In the emergency department he received lorazepam [4 mg] twice, [five] minutes apart, and at [15] minutes he was still seizing. His glucose was [118] mg/dL.

Question: in adults over 65 with benzodiazepine-refractory convulsive status epilepticus (P), is levetiracetam (I) compared with fosphenytoin (C) associated with better seizure cessation, safety and fit with the patient's other treatment (O)?

Efficacy: The Trial Found No Winner

The Established Status Epilepticus Treatment Trial randomized 384 children and adults with benzodiazepine-refractory status epilepticus to levetiracetam, fosphenytoin or valproate, in a blinded design with response-adaptive randomization (Kapur et al., 2019). The primary outcome, cessation of seizures with improving responsiveness at 60 minutes without additional drugs, occurred in 47 percent with levetiracetam, 45 percent with fosphenytoin and 46 percent with valproate. The trial was stopped at a planned interim analysis for futility, meaning that further enrollment was unlikely to show one drug to be better or worse than the others.

Futility is not proof that the drugs are identical. It means that any difference large enough to matter clinically was unlikely to be found. The extended enrollment, analyzed by age, included 51 adults over 65; in that group the primary outcome was met in 37 percent with levetiracetam and 35 percent with fosphenytoin, with no detectable difference in efficacy or in the primary safety outcome (Chamberlain et al., 2020). The small older group makes those estimates imprecise, but they agree with the main result.

The American Epilepsy Society guideline, published before ESETT, reached a similar position: fosphenytoin, valproic acid and levetiracetam are all acceptable second-line options, with no evidence-based preference among them (Glauser et al., 2016).

When two drugs work equally well, the choice passes from the trial to the patient in front of you.

What Differs: Interactions

Fosphenytoin is converted to phenytoin, a potent inducer of hepatic enzymes, including CYP3A4, and of P-glycoprotein. Apixaban is cleared by both pathways. The EHRA practical guide on direct oral anticoagulants advises avoiding combined use of apixaban with strong inducers such as phenytoin, because the anticoagulant's levels fall and its protection against stroke may be lost (Steffel et al., 2021). The effect is not immediate after a single loading dose, but a second-line agent chosen in the emergency department often becomes the maintenance drug. For a man with atrial fibrillation and a previous stroke, a drug that quietly lowers his anticoagulant levels over the following weeks carries a real cost.

Levetiracetam has no clinically important interaction with apixaban. It is cleared by the kidneys, and his creatinine clearance of [68] mL/min allows a standard loading dose of [60 mg/kg], up to [4,500] mg, as used in ESETT.

What Differs: The Heart

Fosphenytoin can cause hypotension and cardiac arrhythmia, particularly when infused quickly, and requires continuous cardiac and blood pressure monitoring during the infusion. Mr. [V.] has atrial fibrillation and takes a rate-controlling drug. Levetiracetam has no meaningful effect on cardiac conduction or blood pressure at loading doses. In ESETT, rates of hypotension and life-threatening arrhythmia were low and did not differ significantly among the drugs, but the trial was not large enough to exclude modest differences in older adults with heart disease.

What Differs: Practicalities at the Bedside

Speed and monitoring also favor one drug slightly. Levetiracetam can be given as a single infusion over about [ten] minutes and needs no special monitoring beyond what any patient in status epilepticus already has. Fosphenytoin is dosed in phenytoin equivalents, [20] mg PE per kilogram, and is limited to a maximum infusion rate, [150] mg PE per minute, because faster infusion raises the risk of hypotension and arrhythmia; for Mr. [V.], at [84] kg, that means at least [11] minutes, with continuous ECG and blood pressure monitoring throughout. In a busy resuscitation bay, a drug that needs fewer checks is less likely to be given too fast or interrupted.

The choice also shapes what happens next. If levetiracetam controls his seizures, it can be continued by mouth at a maintenance dose adjusted for his kidney function, with no effect on his apixaban. If fosphenytoin controls them, continuing phenytoin would require either changing his anticoagulant or accepting a known interaction, and phenytoin's nonlinear kinetics would require level monitoring in an older adult. A second-line drug that works in the emergency department and can simply be continued afterward saves the next team a difficult decision.

Other Considerations

Valproate is the third option with equal efficacy. It was not chosen for Mr. [V.] because it can cause thrombocytopenia and platelet dysfunction, which adds bleeding risk on top of an anticoagulant. Levetiracetam's main adverse effects in older adults are somnolence and, less often, agitation or mood change, which are manageable and reversible. His family will be told to report any change in mood or behavior in the weeks after discharge.

Recommendation

For Mr. [V.], levetiracetam [60 mg/kg], maximum [4,500] mg, intravenously over [ten] minutes is the recommended second-line agent. The trial evidence does not favor either drug on seizure control. The decision rests on two patient-specific differences: fosphenytoin would reduce his apixaban levels through enzyme induction, and it carries cardiac risks that matter more in a man with atrial fibrillation. If seizures continue after levetiracetam, the next step is a third-line agent with airway support in intensive care, and fosphenytoin would then be reconsidered with the interaction managed rather than avoided.

Limitations

ESETT enrolled few older adults, and its age-stratified analysis cannot exclude differences in that group. The trial measured seizure cessation at 60 minutes, not longer-term outcomes. The interaction concern is based on pharmacology and labeling rather than on outcome trials in status epilepticus. These limits do not change the recommendation, but they explain why it is framed around the patient's other treatment rather than around efficacy. A future trial powered for older adults, or data on outcomes after discharge, could shift the balance, and the paper's reasoning would then need to be revisited with the new numbers.

References

Chamberlain, J. M., Kapur, J., Shinnar, S., Elm, J., Holsti, M., Babcock, L., Rogers, A., Barsan, W., Cloyd, J., Lowenstein, D., Bleck, T. P., Conwit, R., Meinzer, C., Cock, H., Fountain, N. B., Underwood, E., Connor, J. T., & Silbergleit, R. (2020). Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): A double-blind, responsive-adaptive, randomised controlled trial. The Lancet, 395(10231), 1217-1224. https://doi.org/10.1016/S0140-6736(20)30611-5

Glauser, T., Shinnar, S., Gloss, D., Alldredge, B., Arya, R., Bainbridge, J., Bare, M., Bleck, T., Dodson, W. E., Garrity, L., Jagoda, A., Lowenstein, D., Pellock, J., Riviello, J., Sloan, E., & Treiman, D. M. (2016). Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Currents, 16(1), 48-61. https://doi.org/10.5698/1535-7597-16.1.48

Kapur, J., Elm, J., Chamberlain, J. M., Barsan, W., Cloyd, J., Lowenstein, D., Shinnar, S., Conwit, R., Meinzer, C., Cock, H., Fountain, N., Connor, J. T., & Silbergleit, R. (2019). Randomized trial of three anticonvulsant medications for status epilepticus. New England Journal of Medicine, 381(22), 2103-2113. https://doi.org/10.1056/NEJMoa1905795

Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., Sinnaeve, P., Vanassche, T., Potpara, T., Camm, A. J., & Heidbüchel, H. (2021). 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace, 23(10), 1612-1676. https://doi.org/10.1093/europace/euab065